Highlights Biocon Limited

Equities

BIOCON

INE376G01013

Market Closed - NSE India S.E. Other stock markets 07:43:48 2024-05-10 am EDT			5-day change	1st Jan Change
304 ^INR	+1.79%		-0.39%	+21.77%

Apr. 30	Natural Biocon (India) CFO Passes Away	MT
Apr. 20	Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	Apr. 20	CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	Apr. 17	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	Apr. 17	CI
Biocon Board to Consider Dividend for Fiscal 2024	Apr. 10	MT
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	Apr. 02	MT
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	Mar. 31	CI
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	Mar. 27	CI
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	Mar. 15	MT
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	Mar. 14	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	Mar. 14	RE
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada	Mar. 04	MT
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	Feb. 27	RE
Biocon Swings to Profit in Fiscal Q3	Feb. 09	MT
Indian shares set for a muted start, tracking Asian peers	Feb. 08	RE
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	Feb. 08	RE
Biocon Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Biocon's Biologics Arm Completes Integration of Viatris Biosimilar Business in 120 Countries	Dec. 18	MT
Biocon Reportedly Evaluating Plan to Sell Its Generic Active Pharmaceutical Ingredient Business	Dec. 15	CI
Biocon Denies Plans to Sell $1.5 Billion Generic API Business	Dec. 15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biocon Limited

Equities

BIOCON

INE376G01013

Highlights

Filters